Abstract

9029 Background: New therapies in advanced MEL improve survival, but QoL preservation is uncertain. NIVO (a PD-1 immune checkpoint inhibitor) and IPI are each approved as monotherapy for advanced M...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma.
Chad C Cherington ... Alan H Bryce
Melanoma management | VOL. 2
Chad C Cherington, et. al.Chad C Cherington ... Alan H Bryce
01 Nov 2015
Pharmacoeconomic savings associated with alternate dosing strategy of nivolumab and ipilimumab combination therapy.
Allison Kupsh ... Kathryn J Hammer
Journal of Clinical Oncology | VOL. 38
Allison Kupsh, et. al.Allison Kupsh ... Kathryn J Hammer
10 Oct 2020
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
Fiona Taylor ... Rachael Lawrance
Journal of Clinical Oncology | VOL. 37
Fiona Taylor, et. al.Fiona Taylor ... Rachael Lawrance
20 May 2019
Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
Milton Barros E Silva ... Markus Gifoni
American Journal of Cancer | VOL. 77
Milton Barros E Silva, et. al.Milton Barros E Silva ... Markus Gifoni
01 Jul 2017
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Alexios Matikas ...
Journal of Clinical Oncology | VOL. -
Alexios Matikas, et. al.Alexios Matikas ...
17 Jul 2024
Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
Elias Campo ... Reiner Siebert
Journal of Clinical Oncology | VOL. -
Elias Campo, et. al.Elias Campo ... Reiner Siebert
17 Jul 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Brian C Shaffer ... Monzr M Al Malki
Journal of Clinical Oncology | VOL. -
Brian C Shaffer, et. al.Brian C Shaffer ... Monzr M Al Malki
17 Jul 2024
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
View more papers